Modified Rankin Scale
Assessment of neurologic disability
Další informace
Instrukce a reference
Upozornění
Tento nástroj slouží pouze pro vzdělávací účely a nepředstavuje odborné poradenství ani odborné poradenství nenahrazuje. Tento nástroj není určen k lékařské diagnostice nebo léčbě.
General description
Stroke is one of the leading causes of death and disability worldwide. However, the total burden of poststroke disability can be challenging to quantify.
The modified Rankin Scale (mRS) is a 7-level, clinician-reported measure of global disability in patients post-stroke. It is used to categorize the level of functional independence with reference to pre-stroke activities.
The scale was originally introduced in 1957 by Dr. John Rankin as a 5-level scale ranging from 1 to 5. It was later modified and the modern (modified) version differs from Rankin's original scale mainly in the addition of grade 0, indicating a lack of symptoms, and the addition of grade 6 indicating death.
The mRS has become the most widely employed clinical outcome measure in clinical trials and in large-scale stroke care quality improvement programs. It is formally recommended by regulatory agencies and clinical trial methodology consensus groups worldwide for use in acute stroke clinical trials.
Stroke is one of the leading causes of death and disability worldwide. However, the total burden of poststroke disability can be challenging to quantify.
The modified Rankin Scale (mRS) is a 7-level, clinician-reported measure of global disability in patients post-stroke. It is used to categorize the level of functional independence with reference to pre-stroke activities.
The scale was originally introduced in 1957 by Dr. John Rankin as a 5-level scale ranging from 1 to 5. It was later modified and the modern (modified) version differs from Rankin's original scale mainly in the addition of grade 0, indicating a lack of symptoms, and the addition of grade 6 indicating death.
The mRS has become the most widely employed clinical outcome measure in clinical trials and in large-scale stroke care quality improvement programs. It is formally recommended by regulatory agencies and clinical trial methodology consensus groups worldwide for use in acute stroke clinical trials.
References
Van Swieten, J. C., et al. "Interobserver agreement for the assessment of handicap in stroke patients." stroke 19.5 (1988): 604-607.
Verze
1
O tomto nástroji
Stroke is one of the leading causes of death and disability worldwide. However, the total burden of poststroke disability can be challenging to quantify.
The modified Rankin Scale (mRS) is a 7-level, clinician-reported measure of global disability in patients post-stroke. It is used to categorize the level of functional independence with reference to pre-stroke activities.
The scale was originally introduced in 1957 by Dr. John Rankin as a 5-level scale ranging from 1 to 5. It was later modified and the modern (modified) version differs from Rankin's original scale mainly in the addition of grade 0, indicating a lack of symptoms, and the addition of grade 6 indicating death.
The mRS has become the most widely employed clinical outcome measure in clinical trials and in large-scale stroke care quality improvement programs. It is formally recommended by regulatory agencies and clinical trial methodology consensus groups worldwide for use in acute stroke clinical trials.
The modified Rankin Scale (mRS) is a 7-level, clinician-reported measure of global disability in patients post-stroke. It is used to categorize the level of functional independence with reference to pre-stroke activities.
The scale was originally introduced in 1957 by Dr. John Rankin as a 5-level scale ranging from 1 to 5. It was later modified and the modern (modified) version differs from Rankin's original scale mainly in the addition of grade 0, indicating a lack of symptoms, and the addition of grade 6 indicating death.
The mRS has become the most widely employed clinical outcome measure in clinical trials and in large-scale stroke care quality improvement programs. It is formally recommended by regulatory agencies and clinical trial methodology consensus groups worldwide for use in acute stroke clinical trials.
